ash highlights in cll: moving towards fixed-duration treatment, the role of mrd & alpine results
Published 1 year ago • 156 plays • Length 2:09Download video MP4
Download video MP3
Similar videos
-
6:43
key highlights in cll: clinical trial updates & the role of combination therapies and novel btkis
-
1:00
ash 2022 lba: results from final analysis of alpine - zanubrutinib vs ibrutinib for r/r cll/sll
-
0:56
the current treatment landscape in cll
-
8:04
key presentations in cll treatment at ash 2020
-
1:47
ash cll highlights: ibrutinib-venetoclax combination & undetectable mrd in ighv-mutated patients
-
1:35
highlights of ash in cll
-
1:49
key clinical trials in cll at ash 2020
-
3:13
ash 2014: the management of cll
-
2:33
ash highlights in cll and lymphoma by dr andrew zelenetz
-
1:08
advances in cll at ash 2020: combination therapies
-
0:41
ash 2021 highlights in cml
-
3:08
aml highlights from ash 2017
-
8:42
updates in the aml field at ash 2020
-
6:09
what were the cll highlights at ash 2020?
-
2:13
highlights in cll at ash 2020
-
1:58
comparing the safety & efficacy of reversible and irreversible btk inhibitors in cll
-
2:03
cll progression since ash 2018
-
3:35
an insight into time-limited therapy in cll
-
2:26
pivotal findings at ash 2020